Drug intelligence / Profile preview

tislelizumab + SOX + HIPEC

Development stage: Unknown
Lead developer: BeiGene
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous, Oral, Intraperitoneal

Overview

Tislelizumab + SOX + HIPEC is an investigational combination treatment regimen being evaluated for the treatment of gastric cancer with peritoneal metastasis. The regimen integrates systemic immunotherapy, systemic chemotherapy, and locoregional therapy. It consists of **tislelizumab**, a humanized IgG4 monoclonal antibody that targets the programmed death-1 (PD-1) receptor to enhance anti-tumor T-cell responses; the **SOX regimen**, a standard systemic chemotherapy combination comprising the oral fluoropyrimidine **S-1** (tegafur/gimeracil/oteracil) and the platinum-based agent **oxaliplatin**; and **hyperthermic intraperitoneal chemotherapy (HIPEC)**, which in this specific clinical context utilizes **docetaxel**. This triple-modality approach is being studied by Southwest Hospital in China to improve surgical conversion rates and overall survival in patients with advanced gastric cancer that has spread to the peritoneum, a population typically associated with a poor prognosis.

Other names: Tislelizumab + SOX + HIPECTislelizumab + S-1 + Oxaliplatin + Docetaxel (HIPEC)Tislelizumab + S-1 + Oxaliplatin + Docetaxel

Targets

PDCD1 (Programmed cell death protein 1 receptor)TS (Thymidylate synthase)DNA

Beyond the preview

Go deeper on tislelizumab + SOX + HIPEC.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on tislelizumab + SOX + HIPEC.

Explore the full profile